Inhibikase dismisses CohnReznick, appoints Deloitte as new auditor

Inhibikase Therapeutics, Inc.

Dismissed CohnReznick effective Aug 21, 2026; no disagreements on accounting principles or practices.
Appointed Deloitte & Touche as independent auditor for FY2026, effective immediately after dismissal.
CohnReznick's audit reports for FY2024 and FY2025 were unqualified; no adverse or modified opinions.
Material weakness in internal control over financial reporting disclosed in Q2 2024 was remediated by Q3 2024.
CohnReznick letter to SEC dated Aug 26, 2026 filed as Exhibit 16.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.